Evidence map›Paper›PMID 37850841›Full record

ArticleCancer research communications2023

Exogenous Sequences in Tumors and Immune Cells (Exotic): A Tool for Estimating the Microbe Abundances in Tumor RNA-seq Data.

Rebecca Hoyd, Caroline E Wheeler, YunZhou Liu, Malvenderjit S Jagjit Singh, Mitchell Muniak, Ning Jin, Nicholas C Denko, David P Carbone, Xiaokui Mo, Daniel J Spakowicz

Open access · goldAbstract read
In one paragraph

Article in Cancer research communications, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
3.4field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Rebecca HoydDivision of Medical Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.ORCID 0000-0003-1210-4491
Caroline E WheelerDivision of Medical Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.ORCID 0000-0002-3374-4909
YunZhou LiuDivision of Medical Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.ORCID 0000-0002-9892-2438
Malvenderjit S Jagjit SinghDivision of Medical Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.ORCID 0000-0001-8198-9153
Mitchell MuniakDivision of Medical Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.ORCID 0000-0001-9919-1457
Ning JinDivision of Medical Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.ORCID 0000-0002-6689-4671
Nicholas C DenkoThe Pelotonia Institute for Immuno-Oncology, The Ohio State University Comprehensive Cancer Center - James Cancer Hospital, and Solove Research Institute, Columbus, Ohio.ORCID 0000-0001-6875-734X
David P CarboneDivision of Medical Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.ORCID 0000-0003-3002-1921
Xiaokui MoDepartment of Biomedical Informatics, The Ohio State University College of Medicine, Columbus, Ohio.ORCID 0000-0002-9797-2687
Daniel J SpakowiczDivision of Medical Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.ORCID 0000-0003-2314-6435
The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute · USThe Ohio State University · US

Funding

Translational Therapeutics Research Program (TT)P30CA016058 · NCI · OHIO STATE UNIVERSITY · PI Jennifer A. Woyach · 1985 to 2026
$132.3M
The Ohio State University Center for Clinical and Translational Science (UL1)UL1TR000090 · NCATS · OHIO STATE UNIVERSITY · PI JACKSON, REBECCA D · 2012 to 2013
$7.9M
Overcoming Hypoxic Resistance in Non-Small Cell Lung Cancer By Targeting Mitochondrial MetabolismR01CA262388 · NCI · OHIO STATE UNIVERSITY · PI DENKO, NICHOLAS C., LI, ZIHAI · 2021 to 2025
$3.6M
Overcoming hypoxic resistance to anti-cancer therapyR01CA255334 · NCI · OHIO STATE UNIVERSITY · PI DENKO, NICHOLAS C., LI, ZIHAI · 2021 to 2025
$2.9M
Autism Speaks AS1695NCATS NIH HHS UL1 TR000090NCI NIH HHS P30 CA016058NCI NIH HHS R01 CA255334NCI NIH HHS R01 CA262388
6 · The paper itself

Abstract

The microbiome affects cancer, from carcinogenesis to response to treatments. New evidence suggests that microbes are also present in many tumors, though the scope of how they affect tumor biology and clinical outcomes is in its early stages. A broad survey of tumor microbiome samples across several independent datasets is needed to identify robust correlations for follow-up testing. We created a tool called {exotic} for "exogenous sequences in tumors and immune cells" to carefully identify the tumor microbiome within RNA sequencing (RNA-seq) datasets. We applied it to samples collected through the Oncology Research Information Exchange Network (ORIEN) and The Cancer Genome Atlas. We showed how the processing removes contaminants and batch effects to yield microbe abundances consistent with non-high-throughput sequencing-based approaches and DNA-amplicon-based measurements of a subset of the same tumors. We sought to establish clinical relevance by correlating the microbe abundances with various clinical and tumor measurements, such as age and tumor hypoxia. This process leveraged the two datasets and raised up only the concordant (significant and in the same direction) associations. We observed associations with survival and clinical variables that are cancer specific and relatively few associations with immune composition. Finally, we explored potential mechanisms by which microbes and tumors may interact using a network-based approach. Alistipes, a common gut commensal, showed the highest network degree centrality and was associated with genes related to metabolism and inflammation. The {exotic} tool can support the discovery of microbes in tumors in a way that leverages the many existing and growing RNA-seq datasets. SIGNIFICANCE: The intrinsic tumor microbiome holds great potential for its ability to predict various aspects of cancer biology and as a target for rational manipulation. Here, we describe a tool to quantify microbes from within tumor RNA-seq and apply it to two independent datasets. We show new associations with clinical variables that justify biomarker uses and more experimentation into the mechanisms by which tumor microbiomes affect cancer outcomes.

Indexed as

MicrobiotaNeoplasmsHumansRNA, NeoplasmRNA-SeqSequence Analysis, RNARNA, Neoplasm

Identifiers

PMID37850841
PMCPMC10662017
OpenAlexW4387729581

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.